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A previous study involving tube IATs, untreated RBCs, and a low-
ionic-strength additive reagent revealed that approximately one-
third of R1R1 patients with anti-E have a concomitant anti-c.
However, the current study finds a much higher incidence of anti-c
in such patients, using gel technology in conjunction with ficin-
pretreated RBCs. Results of antibody identification studies and
transfusion records of 82 R1R1 patients with anti-E were reviewed.
Serologic test methods included a LISS wash solution for tube IATs
(15 min at 37°C, anti-IgG), ficin-tube IATs (30 min at 37°C, anti-IgG
+ anti-C3), and gel IATs (untreated or ficin-treated RBCs or both,
anti-IgG gels). LISS-tube or gel IATs with untreated RBCs revealed
anti-c in 32 patients with anti-E. When gel-IAT and ficin-pretreated
RBCs were used, 21 additional patients with anti-E were found to
have anti-c. In samples from 26 R1R1 patients with anti-E, anti-c was
not demonstrable by ficin-gel IATs, and in 3 cases, the ficin-gel tests
were inconclusive. In five cases in which E– RBCs not tested for c
antigen were transfused to patients found by ficin-gel IAT to be
without anti-c, all subsequently performed crossmatches with E–, c-
untested RBCs were compatible. The incidence of anti-c in R1R1
patients with anti-E in this study was 32 of 82 (39%) with untreated
RBCs and 53 of 82 (65%) when the ficin gel data were included.
The latter is significantly higher than the 32 percent incidence
previously reported (p = 0.0001). Accordingly, all patients at our
facility with an Rh antibody are now tested for those additional Rh
antibodies they can make, as predicted from their Rh phenotype.
The data from this study strongly support the selection of R1R1
RBCs for all c– patients with anti-E. Immunohematology
2005;21:94–96.
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The immune response to RhCE protein is variable.
For example, R1R1 (c–, E–) individuals may make anti-c,
anti-E, anti-c plus anti-E, or anti-cE (Rh 27), the latter
reacting with a determinant encoded by c and E within
the same haplotype (in cis). Some individuals may
make all three antibodies, as demonstrated by
adsorption-elution studies,1 or a combination of anti-c
plus anti-E.
Shirey et al.2 found the incidence of anti-c in R1R1
patients with anti-E to be 32 percent when performing
IATs by a low-ionic-strength additive technique. They
also showed if the RBCs selected for transfusion were
E– but not tested for c antigen, 18.5 percent of
recipients developed anti-c. Since their report, gel
technology has emerged and has been found to have
good sensitivity for Rh antibodies. Further, we have
shown that tests performed with anti-IgG gel cards and
ficin-pretreated RBCs are exquisitely sensitive for Rh
antibodies.3
In this report we present data from ficin-gel tests
that demonstrate a higher than previously published
incidence of anti-c in R1R1 patients with anti-E. These
data support the selection of c– RBCs for this patient
population.
Materials and Methods
ID-MTS gel technology was from Ortho-Clinical
Diagnostics (Raritan,NJ). Reagent RBCs,both untreated
and ficin-treated, and LISS (Löw and Messeter4
formulation) were from ImmucorGamma, Norcross,
Georgia. For gel testing,5 untreated reagent RBCs were
prepared in ID-MTS Diluent 2 at a concentration of 0.8%
and tested on anti-IgG cards according to the
manufacturer’s product circular. Gel tests with ficin-
pretreated RBCs were similarly performed on anti-IgG
cards; such testing (previously validated by us3)
conflicts with the manufacturer’s product circular,
which stipulates the use of buffered gel cards. LISS-tube
tests6 were incubated at 37°C for 15 minutes, washed
four times with saline, and tested with anti-IgG (Ortho).
Ficin-tube tests6 were incubated at 37°C for 30 minutes
and tested with polyspecific (anti-IgG + C3) anti-
globulin reagent (Ortho). Negative tube tests were
validated with IgG-coated RBCs (ImmucorGamma).
Serologic and transfusion records of 82 R1R1
patients with anti-E were reviewed. No further testing
was performed on 32 patients with concomitant anti-c
by routine testing (LISS-tube and ficin-tube). Ficin-gel
tests were used to detect the presence or absence of
anti-c in samples from the remaining 50 patients.
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Results
We found anti-c in 53 out of 82 (65%) R1R1 patients
with anti-E (Table 1). In 32 cases, the presence of anti-
c was evident from the results of LISS-tube or gel IATs.
In the other 21 cases (see Fig. 1 for an example), the
presence of anti-c was clearly demonstrable only in
ficin-gel IATs. However, among these 21 cases, weak
reactivity was also seen in two cases with some
untreated c+, E– RBCs in gel IATs and suspected from
the results of ficin-tube tests in five cases. There were
three additional cases in which the presence of anti-c
could not be determined due to panreactivity in ficin-
gel tests.
Of the 26 R1R1 patients with anti-E that did not have
anti-c clearly demonstrable by ficin gel, 18 did not
require transfusion (five were pregnant, and there were
records of previous transfusions on six). A further
eight patients were transfused with E– RBCs that were
not tested for c antigen. Three of these patients were
lost to follow-up. We had the opportunity to test the
five remaining patients for anti-c in subsequent
antiglobulin crossmatches with E– donor units that had
not been selected to be c–; in fact, two patients were
transfused with Rh– RBCs that were undoubtedly c+.
These crossmatches were performed between 3 and 20
months after anti-E was initially detected in the
patients’ plasma. All units (n = 10) were crossmatch
compatible.
Discussion
The development of alloantibodies to RBC antigens
through transfusion or pregnancy is not benign.
Patients who become alloimmunized are at risk of
hemolytic transfusion reactions and high-risk
pregnancies associated with HDN.7,8 Further,
alloimmunization is sometimes accompanied by
autoantibody formation, which may lead to
autoimmune hemolytic anemia.9 These risks prompted
some investigators to recommend the use of
phenotypically matched RBCs, especially for sickle cell
anemia patients.10 As shown recently,11,12 this
recommendation is by no means universally followed.
In the 11th edition of the AABB Technical
Manual,13 it was suggested that R1R1 transfusion
candidates who have made anti-E should be transfused
with R1R1 RBCs to prevent formation of anti-c, possible
posttransfusion hemolysis, and autoantibody forma-
tion. This suggestion prompted Shirey and colleagues2
to determine the incidence of anti-c in 100 R1R1
patients with anti-E. In their study,using LISS-tube IATs,
they found the incidence to be 32 percent. Among the
68 R1R1 patients with anti-E alone, 27 were transfused
with E– RBCs that were not typed for c antigen; five
(18.5%) of these patients subsequently formed anti-c.
Given our past experiences with gel technology,14
which is exquisitely sensitive for Rh antibodies, we
expected to find a somewhat higher incidence of anti-
c in R1R1 patients with anti-E than was reported by
Shirey et al.2 However, we did not expect to find a
twofold increase (32% vs.65%;p = 0.0001) through the
use of gel technology and ficin-treated RBCs, given that
before implementation of gel technology in our
laboratory our routine antibody identification protocol
included ficin-tube IATs. We postulate that these anti-c
antibodies are, for the most part, low-affinity antibodies
Table 1. Incidence of anti-c in 82 R1R1 patients with anti-E
LISS tube or gel Ficin gel Number of patients
anti-E + anti-c NT* 32 (39%)
anti-E anti-E + anti-c 21 (26%)
anti-E anti-E 26 (32%)
anti-E inconclusive 3 (3%)
*NT = not tested
Fig. 1. A. Anti-IgG gel tests with untreated RBCs reveal presence of 
anti-E. B. Tests with ficin-pretreated RBCs reveal presence of
concomitant anti-c.
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that dissociate during the washing phase of tube IATs;
gel technology is, of course, a no-wash IAT.
Although we saw no evidence of anti-c
development in five R1R1 patients with anti-E, as
demonstrated by compatible IAT crossmatches with
E–, c-untested RBCs, we now select c–
blood for R1R1 patients with anti-E,
regardless of whether or not anti-c is
detected. However, due to the compar-
ative rarity of R2R2 donors, we do not
automatically select R2R2 RBCs for
patients with anti-C who are e–. Rather,
we test for anti-e by ficin gel, if it is not
evident by routine studies, and, if it is
present, we crossmatch R2R2 donor RBCs. We have a
similar policy for Ro patients with anti-C or anti-E,
inasmuch as we select C–, E– RBCs for crossmatching
only if ficin-gel tests reveal that both anti-C and anti-E
are present (Table 2).
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Table 2. Policy for ficin-gel testing and blood selection in D+ patients with Rh alloantibodies 
Patient’s RBCs If* ◆ Then† Or, if* ◆ Then†
R1R1 anti-E ◆ issue c–, E– RBCs
R2R2 anti-C ◆ exclude anti-e anti-e ◆ issue C–, e– RBCs
R0 anti-C ◆ exclude anti-E anti-E ◆ exclude anti-C
*Antibody found in serum with untreated RBCs.
†Exclusion tests performed with ficin-treated RBCs by gel technology.
